Meda has reached an agreement with the Spanish pharma company Almirall about a respiratory combination project in the Novolizer device that Meda had certain rights to. The project is in research phase, and Almirall has purchased Meda’s rights for 45 million EUR.

MEDA AB (publ) is a leading international specialty pharma company. Meda’s products are sold in 120 countries worldwide and the company is represented by its own organizations in 50 countries. The Meda share is listed under Large Cap on the Nasdaq OMX Nordic Stock Exchange in Stockholm. Find out more, visit www.meda.se.